OpenGate Capital Enters into Binding Agreement to Sell Fiven
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has entered into a binding agreement for the sale of Fiven, a worldwide leading producer of Silicon Carbide (“SiC”), to Kymera International, a portfolio company of Palladium Equity Partners, LLC. Terms of the agreement were not disclosed.
OpenGate acquired Fiven in 2019 through a corporate carve-out from Saint-Gobain.
Fiven SiC grains and powders offer unique properties of hardness, thermal resistance and conductivity, wear resistance, and chemical inertness. Fiven products are sold to a diverse customer base across Europe, South America, and North America for use in a wide array of applications including metallurgy, refractory, abrasives, filtration, and technical ceramics. Fiven has a global manufacturing footprint across Norway, Belgium, and Brazil and is headquartered in Oslo, Norway.
The transaction is subject to customary regulatory approvals and is expected to close in Q3 2024.
About OpenGate Capital
OpenGate Capital is a global private equity firm specializing in the acquisition and operation of businesses to create new value through operational improvements, innovation, and growth. Established in 2005, OpenGate Capital is headquartered in Los Angeles, California with a European office in Paris, France. OpenGate’s professionals possess the critical skills needed to acquire, transition, operate, build, and scale successful businesses. To date, OpenGate Capital has executed more than 40 platform acquisitions across North America and Europe. To learn more about OpenGate, please visit www.opengatecapital.com.
About Kymera International
Kymera International, through acquisitions, can trace its roots back to the 1800’s. Today, Kymera International is a U.S. owned, leading global developer and manufacturer of advanced specialty materials and high-performance surface coatings. Kymera sells its technically developed products into a wide variety of end markets, including aerospace, defense, medical, electronics, chemical, specialty auto, additive manufacturing, and numerous industrial applications. Kymera International has manufacturing facilities in the U.S., Canada, Australia, Europe, UK and Asia. For more information, please visit www.kymerainternational.com.
About Palladium Equity Partners, LLC
Since its founding in 1997, Palladium has invested in more than 210 companies (40 platforms and more than 170 add-ons). With over $3 billion in AUM, the firm focuses primarily on buyout equity investments in the range of $50 million to $150 million. Palladium seeks to acquire and grow companies in partnership with founders and experienced management teams by providing capital and strategic guidance. The partners of the firm have meaningful experience in consumer, services, industrials, and healthcare businesses, with a focus on companies they believe will benefit from the growth in the U.S. Hispanic population. For more information, please visit www.palladiumequity.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604317098/en/
Contact information
OpenGate Media Contacts:
Prosek Partners
Email: Pro-opengate@prosek.com
Alanna Chaffin
Head of Investor Relations & Communications
Email: AChaffin@opengatecapital.com
Telephone: +1 310-432-7000
OpenGate Origination Contact:
Joshua Adams
Partner
Email: jadams@opengatecapital.com
Telephone: +1 310-432-7000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale19.12.2025 15:00:00 EET | Press release
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platform capable of testing thousands of genetic variants in parallel and measuring their effects at single cell resolution. By combining Codebreaker’s synthetic biology platform and variant engineering capabilities with the scale and accessibility of Parse’s Evercode™ technology, the collaboration aims to generate the causal data increasingly sought by AI developers, drug discovery teams, and clinical researchers. Today’s genomic studies rely heavily on observational data, or variants that appear in large populations. But rare and private variants, often only seen in one individual or family, are nearly impossible to study this way because too few carriers of the variant exist to draw statistically meaningful conclusions. As a result, even the most advanced models trained on observational datas
Cyviz Awarded Two Classified NATO Defense Contracts19.12.2025 09:00:00 EET | Press release
Norwegian technology and platform company Cyviz AS has been awarded two classified defense contracts by major European NATO-partner nations to deliver a fully mobile, containerised Command & Control (C2) capability, strengthening Europe’s operational readiness in high-threat and expeditionary environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218625485/en/ Image from a previous military exercise where Cyviz demonstrated a mobile command center solution. The contracts cover the design, integration, and delivery of secure, deployable operations centres engineered to NATO security standards, enabling military and security forces to establish full theatre-class command capability wherever operations require. Due to the sensitive nature of the missions, contract value and customer identities remain undisclosed. From Demonstrated Readiness to Operational Deployment The awards follow growing interest among European def
S3NS Announces SecNumCloud Qualification for PREMI3NS, its Trusted Cloud Offering19.12.2025 08:00:00 EET | Press release
S3NS, a subsidiary of Thales in partnership with Google Cloud, today announced that PREMI3NS, its "Trusted Cloud" (Cloud de confiance) offering, has received the SecNumCloud 3.2 qualification delivered by the French National Agency for the Security of Information Systems (ANSSI). Meeting SecNumCloud 3.2’s protection and resilience requirements, which are known as the most demanding ones in France and Europe, it offers immunity from non-European extraterritorial laws. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218817208/en/ ANSSI delivered the SecNumCloud 3.2 qualification for S3NS’ PREMI3NS offering, meeting all its requirements and passing all three milestones of the qualification process. With PREMI3NS, S3NS now offers businesses and public sector organizations the most extensive cloud service among the offerings that have received the SecNumCloud 3.2 qualification. PREMI3NS integrates the most advanced IaaS and Paa
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 03:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 01:34:00 EET | Press release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom